InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: PhoenixRising post# 180843

Monday, 06/23/2014 11:20:50 AM

Monday, June 23, 2014 11:20:50 AM

Post# of 346551

My point,and mine only, is for PPHM to FOCUS on what they have NOW working in trials



I agree.... and overall, just like to point out that now "well" over a thousand publications exist on Phosphatidylserine ( flipped-PS ) and on many more conditions than Peregrine could afford to run trials on. Since partnership, collaborations..etc are all on every ones mind .... wouldn't every single condition that contains flipped PS want to have a little PS Targeting agents such as Bavi to re-do their research or experiments or trials... etc ?

I just think that is the bottom line. Big Pharma been trying to get Peregrine for pennies on the dollar for what they will eventually be worth. We know they have a plan and I'm looking forward to how they bring in some value that will make the shareholders happy... instead of guessing and wondering and speculating

time will tell...

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News